Sugi Predict

Sugi Predict / Compounds / SCHEMBL197441

SCHEMBL197441

SCHEMBL197441

Cc1ccccc1-c1ccccc1P(C1CCCCC1)C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.36
▸ S1PR5 Q9H228 1/20 0.36
▸ SIGMAR1 Q99720 3/20 0.36
▸ GRIN2D O15399 1/20 0.35
▸ GRIN3B O60391 1/20 0.35
▸ GRIN1 Q05586 1/20 0.35
▸ GRIN2A Q12879 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ GRIN2C Q14957 1/20 0.35
▸ GRIN3A Q8TCU5 1/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ P2RX7 Q99572 2/20 0.33
▸ HTR7 P34969 1/20 0.33
▸ CNR1 P21554 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ PLA2G7 Q13093 1/20 0.32
▸ BCHE P06276 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29350531 1.00 S1PR1 (0.36) S1PR1S1PR5SIGMAR1GRIN2DGRIN3B
SCHEMBL29391022 1.00 S1PR1 (0.36) S1PR1S1PR5SIGMAR1GRIN2DGRIN3B
SCHEMBL520084 0.89 BCHE (0.37) BCHEACHESMN1; SMN2ROCK2
SCHEMBL645784 0.87 DDB1 (0.38) S1PR1S1PR5SIGMAR1GRIN2DGRIN3B
SCHEMBL301552 0.85 NPC1 (0.38) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29584884 0.85 SIGMAR1 (0.35) S1PR1S1PR5SIGMAR1GRIN2DGRIN3B
SCHEMBL3929841 0.85 SIGMAR1 (0.35) S1PR1S1PR5SIGMAR1GRIN2DGRIN3B
SCHEMBL3165316 0.84 NPC1 (0.37) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17930296 0.84 HDAC1 (0.32) S1PR1S1PR5SIGMAR1GRIN2DGRIN3B
SCHEMBL3185842 0.83 TSHR (0.36) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 982 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725945-A1 PREPARATION METHOD FOR FORMAMIDE COMPOUNDS Shanghai Senhui Medicine Co., Ltd. (CN) 2026-04-15 — — EP claimed
EP-2427468-B2 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2025-06-04 — — EP claimed
WO-2024251227-A1 PREPARATION METHOD FOR FORMAMIDE COMPOUNDS 上海森辉医药有限公司 2024-12-12 — — WO claimed
US-20240300922-A1 PROCESS FOR PREPARING EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2024-09-12 — — US claimed
CN-118059887-A Preparation method and application of catalyst for preparing organic carboxylic ester by olefine hydrogen esterification 中国科学院大连化学物理研究所 2024-05-24 — — CN claimed
EP-4359401-A1 PROCESS FOR PREPARING EGFR INHIBITORS Blueprint Medicines Corporation (US) 2024-05-01 — — EP claimed
EP-4267591-A2 ORGANOMETALLIC COMPOUNDS Umicore AG & Co. KG (DE) 2023-11-01 — — EP claimed
CN-114478582-B Conjugated fused macrocyclic material containing phenothiazine, and preparation method and application thereof 复旦大学 2023-10-10 — — CN claimed
CN-116802187-A Organometallic compounds 优米科尔股份公司及两合公司 2023-09-22 — — CN claimed
CN-115806562-A Method for constructing boron-substituted xanthene dye through palladium-catalyzed cross coupling and application 华东师范大学 2023-03-17 — — CN claimed
WO-2004089934-A1 PROCESSES FOR THE PREPARATION OF N-((((PYRIDINYLOXY) -PHENYLAMINO) QUINAZOLINYL)- ALLYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS WELL AS INTERMEDIATES OF SUCH PROCESSES AND PROCESSES FOR THE PREPARATION OF SUCH INTERMEDIATES PFIZER PRODUCTS INC. (US) 2004-10-21 — — WO claimed
US-20040198997-A1 Copper complexes and their use LANXESS DEUTSCHLAND GMBH (DE) 2004-10-07 — — US claimed
JP-2004527556-A — — 2004-09-09 — — JP claimed
EP-1437356-A1 Copper complexes and the use thereof Bayer Chemicals AG (DE) 2004-07-14 — — EP claimed
US-6689897-B2 CHOLESTERYL ESTER TRANSFER PROTEIN PFIZER INC. 2004-02-10 — — US claimed
EP-1383734-A2 COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES Pfizer Products Inc. (US) 2004-01-28 — — EP claimed
WO-2002088069-A9 COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES PFIZER PROD INC (US) 2003-12-04 — — WO claimed
US-20030144506-A1 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC. 2003-07-31 — — US claimed
US-20020177716-A1 Intermediates of CETP inhibitors DAMON DAVID B (US) 2002-11-28 — — US claimed
WO-2002088069-A2 COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2002-11-07 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198997-A1 Copper complexes and their use SOD1, SOD3, ITPA S1PR1 4579/4885S1PR5 4565/4885SIGMAR1 2264/4885
US-20240300922-A1 PROCESS FOR PREPARING EGFR INHIBITORS EGFR, ERBB2, ERBB4 S1PR1 1603/4885S1PR5 1403/4885SIGMAR1 1776/4885
US-20030144506-A1 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNE1, CCNT1 S1PR1 201/4885S1PR5 337/4885SIGMAR1 1927/4885
US-20020177716-A1 Intermediates of CETP inhibitors CETP, LCAT, MTTP S1PR1 573/4885S1PR5 397/4885SIGMAR1 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.